Palisade Bio (NASDAQ:PALI) Raised to Hold at Wall Street Zen

Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research analysts also recently issued reports on PALI. Citigroup reiterated a “buy” rating on shares of Palisade Bio in a report on Tuesday, November 11th. Piper Sandler started coverage on shares of Palisade Bio in a research note on Monday, December 29th. They set an “overweight” rating and a $25.00 price target for the company. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a report on Monday, December 29th. B. Riley Financial began coverage on shares of Palisade Bio in a report on Friday, January 9th. They set a “buy” rating and a $7.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.25.

Palisade Bio Trading Down 4.3%

Shares of NASDAQ PALI opened at $1.77 on Friday. The company has a fifty day moving average price of $1.86 and a 200 day moving average price of $1.58. The firm has a market cap of $263.73 million, a PE ratio of -0.83 and a beta of 1.58. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.64.

Hedge Funds Weigh In On Palisade Bio

Institutional investors have recently added to or reduced their stakes in the company. Total Clarity Wealth Management Inc. acquired a new stake in Palisade Bio in the fourth quarter valued at $70,000. Jefferies Financial Group Inc. bought a new stake in shares of Palisade Bio in the 4th quarter valued at about $110,000. Geode Capital Management LLC lifted its stake in Palisade Bio by 5,780.7% in the 4th quarter. Geode Capital Management LLC now owns 1,565,452 shares of the company’s stock valued at $3,681,000 after purchasing an additional 1,538,832 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Palisade Bio in the 4th quarter valued at about $1,310,000. Finally, TD Asset Management Inc bought a new position in Palisade Bio during the fourth quarter worth about $480,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.